利民股份(002734.SZ):與植生優谷簽署戰略合作協議
格隆匯9月25日丨利民股份(002734.SZ)公佈,2024年9月23日,利民控股集團股份有限公司與上海植生優谷生物技術有限公司(以下簡稱“植生優谷”)簽署了《戰略合作協議》,雙方將基於各自的戰略佈局和業務優勢,共同致力於合成生物學技術,共同創制研發、推廣應用新型RNA生物農藥產品。進一步提高公司的核心競爭力和持續發展能力,為農業安全、綠色、健康發展做出貢獻。
雙方共同創制開發具有靶向性強、環境友好、施用方便、成本低的新型RNA生物農藥;展開基於科技成果轉化的登記申報、技術交流、生產製造、標準制定、品牌共建、市場推廣等方面深度合作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.